| __timestamp | Bristol-Myers Squibb Company | Supernus Pharmaceuticals, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 5699000000 | 72471000 |
| Thursday, January 1, 2015 | 5001000000 | 89204000 |
| Friday, January 1, 2016 | 5002000000 | 106010000 |
| Sunday, January 1, 2017 | 4849000000 | 137905000 |
| Monday, January 1, 2018 | 4551000000 | 159888000 |
| Tuesday, January 1, 2019 | 4871000000 | 158425000 |
| Wednesday, January 1, 2020 | 7661000000 | 200677000 |
| Friday, January 1, 2021 | 7690000000 | 304759000 |
| Saturday, January 1, 2022 | 7814000000 | 377221000 |
| Sunday, January 1, 2023 | 7772000000 | 336361000 |
| Monday, January 1, 2024 | 8414000000 |
In pursuit of knowledge
In the ever-evolving pharmaceutical industry, understanding the financial dynamics of major players is crucial. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of two prominent companies: Bristol-Myers Squibb Company and Supernus Pharmaceuticals, Inc., from 2014 to 2023.
Bristol-Myers Squibb, a titan in the industry, consistently reported SG&A expenses averaging around $6 billion annually. Notably, their expenses surged by approximately 70% from 2019 to 2020, reflecting strategic investments or market shifts. In contrast, Supernus Pharmaceuticals, a smaller entity, maintained a more modest average of $194 million, with a notable 420% increase over the decade, indicating significant growth and expansion efforts.
This financial juxtaposition highlights the diverse strategies and scales of operation within the pharmaceutical sector, offering insights into how companies allocate resources to maintain competitive edges.
Eli Lilly and Company vs Supernus Pharmaceuticals, Inc.: SG&A Expense Trends
Operational Costs Compared: SG&A Analysis of Johnson & Johnson and Bristol-Myers Squibb Company
Selling, General, and Administrative Costs: Novartis AG vs Supernus Pharmaceuticals, Inc.
Bristol-Myers Squibb Company or Zoetis Inc.: Who Manages SG&A Costs Better?
Selling, General, and Administrative Costs: Bristol-Myers Squibb Company vs Neurocrine Biosciences, Inc.
Bristol-Myers Squibb Company and Blueprint Medicines Corporation: SG&A Spending Patterns Compared
Operational Costs Compared: SG&A Analysis of Bristol-Myers Squibb Company and Agios Pharmaceuticals, Inc.
Who Optimizes SG&A Costs Better? Teva Pharmaceutical Industries Limited or Supernus Pharmaceuticals, Inc.
Who Optimizes SG&A Costs Better? Biogen Inc. or Supernus Pharmaceuticals, Inc.
Who Optimizes SG&A Costs Better? Pharming Group N.V. or Supernus Pharmaceuticals, Inc.
Who Optimizes SG&A Costs Better? Verona Pharma plc or Supernus Pharmaceuticals, Inc.
Comparing SG&A Expenses: Supernus Pharmaceuticals, Inc. vs Amphastar Pharmaceuticals, Inc. Trends and Insights